SCHEMBL3024327

SCHEMBL3024327

CCn1c(NCc2ccccc2O)nc2ccccc21

nearest known ligand 0.77

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 7/20 0.77
MAPT P10636 7/20 0.77
MAPK1 P28482 2/20 0.77
HPGD P15428 1/20 0.77
NPSR1 Q6W5P4 2/20 0.74
SMN1; SMN2 Q16637 4/20 0.73
NPC1 O15118 1/20 0.73
RAB9A P51151 1/20 0.73
HTT P42858 2/20 0.72
TP53 P04637 5/20 0.67
PKM P14618 3/20 0.67
USP2 O75604 2/20 0.67
MEN1 O00255 2/20 0.67
KMT2A Q03164 2/20 0.67
GAA P10253 3/20 0.65
ALOX15 P16050 1/20 0.65
KDM4E B2RXH2 1/20 0.63
POLB P06746 1/20 0.62
LMNA P02545 2/20 0.60
TSHR P16473 1/20 0.57

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3022079 0.90 MAPT (0.86) ALDH1A1MAPTMAPK1HPGDNPSR1
SCHEMBL3024864 0.86 MEN1 (0.83) ALDH1A1MAPTMAPK1HPGDNPSR1
SCHEMBL20715589 0.85 MAPT (0.91) ALDH1A1MAPTMAPK1HPGDNPSR1
SCHEMBL3023642 0.85 MAPT (0.80) ALDH1A1MAPTMAPK1HPGDNPSR1
SCHEMBL3031459 0.85 MAPT (1.00) ALDH1A1MAPTMAPK1HPGDNPSR1
SCHEMBL3024216 0.84 ALDH1A1 (0.73) ALDH1A1MAPTMAPK1HPGDNPSR1
SCHEMBL3021496 0.83 MEN1 (0.76) ALDH1A1MAPTMAPK1HPGDNPSR1
SCHEMBL3026057 0.82 PKM (0.84) ALDH1A1MAPTMAPK1NPSR1SMN1; SMN2
SCHEMBL3022260 0.81 MEN1 (0.76) ALDH1A1MAPTMAPK1HPGDNPSR1
SCHEMBL13166612 0.79 MAPT (0.85) ALDH1A1MAPTMAPK1HPGDNPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20200377505-A1 BENZIMIDAZOLES AND AZA-BENZIMIDAZOLES, AND METHODS OF USE THEREOF GFB (ABC), LLC 2020-12-03 US disclosed
WO-2019028308-A1 BENZIMIDAZOLES AND AZA-BENZIMIDAZOLES, AND METHODS OF USE THEREOF GOLDFINCH BIO, INC. (US) 2019-02-07 WO disclosed
US-9316633-B2 Methods for identifying inhibitors of solute transporters THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2016-04-19 US disclosed
US-20100190796-A1 METHODS FOR IDENTIFYING INHIBITORS OF SOLUTE TRANSPORTERS THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2010-07-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200377505-A1 BENZIMIDAZOLES AND AZA-BENZIMIDAZOLES, AND METHODS OF USE THEREOF AZI2, ATP6V1B1, GLS ALDH1A1 54/4885MAPT 4542/4885MAPK1 4304/4885
US-20100190796-A1 METHODS FOR IDENTIFYING INHIBITORS OF SOLUTE TRANSPORTERS SLC2A1, SLC2A3, SLC2A8 ALDH1A1 3404/4885MAPT 1849/4885MAPK1 2433/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.